**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 64811

**Manuscript Type:** REVIEW

**Clozapine resistant schizophrenia: Newer avenues of management**

Chakrabarti S. Management of clozapine resistance

Subho Chakrabarti

**Subho Chakrabarti,** Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India

**Author contributions:** Chakrabarti S is the sole author of this manuscript.

**Corresponding author: Subho Chakrabarti, MD, Professor,** Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. subhochd@yahoo.com

**Received:** February 23, 2021

**Revised:** April 12, 2021

**Accepted:** July 13, 2021

**Published online:** August 19, 2021

**Abstract**

About 40%-70% of the patients with treatment-resistant schizophrenia have a poor response to adequate treatment with clozapine. The impact of clozapine-resistant schizophrenia (CRS) is even greater than that of treatment resistance in terms of severe and persistent symptoms, relapses and hospitalizations, poorer quality of life, and healthcare costs. Such serious consequences often compel clinicians to try different augmentation strategies to enhance the inadequate clozapine response in CRS. Unfortunately, a large body of evidence has shown that antipsychotics, antidepressants, mood stabilizers, electroconvulsive therapy, and cognitive-behavioural therapy are mostly ineffective in augmenting clozapine response. When beneficial effects of augmentation have been found, they are usually small and of doubtful clinical significance or based on low-quality evidence. Therefore, newer treatment approaches that go beyond the evidence are needed. The options proposed include developing a clinical consensus about the augmentation strategies that are most likely to be effective and using them sequentially in patients with CRS. Secondly, newer approaches such as augmentation with long-acting antipsychotic injections or multi-component psychosocial interventions could be considered. Lastly, perhaps the most effective way to deal with CRS would be to optimize clozapine treatment, which might prevent clozapine resistance from developing. Personalized dosing, adequate treatment durations, management of side effects and non-adherence, collaboration with patients and caregivers, and addressing clinician barriers to clozapine use are the principal ways of ensuring optimal clozapine treatment. At present, these three options could the best way to manage CRS until research provides more firm directions about the effective options for augmenting clozapine response.

**Key Words:** Clozapine-resistance; Augmentation; Medications; Electroconvulsive therapy; Psychosocial treatments; Schizophrenia

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. *World J Psychiatr* 2021; 11(8): 429-448

**URL:** https://www.wjgnet.com/2220-3206/full/v11/i8/429.htm

**DOI:** https://dx.doi.org/10.5498/wjp.v11.i8.429

**Core Tip:** About 40%-70% of patients develop clozapine-resistant schizophrenia, which has serious health, economic, and social consequences. Research on clozapine-resistant schizophrenia has provided little support for the efficacy of psychotropics, electroconvulsive therapy, and cognitive-behavioural therapy in augmenting clozapine non-response. Therefore, newer approaches are needed including a clinical consensus about using the most effective of the currently available augmentation strategies. Augmentation with long-acting antipsychotic injections or multi-component psychosocial interventions could also be tried. Finally, the best option at present may be to prevent clozapine resistance from developing by optimizing clozapine treatment and collaborating with patients and caregivers to ensure its continuation.

**INTRODUCTION**

Although antipsychotic treatment is one of the principal options for the management of schizophrenia, about a third of the patients with schizophrenia do not respond well to first- or second-generation antipsychotics[1,2]. People with treatment-resistant schizophrenia (TRS) continue to have psychotic symptoms and functional impairment despite adequate antipsychotic use. TRS is associated with greater severity of symptoms, more frequent relapses, repeated hospitalizations, poorer socio-occupational functioning, and poorer quality of life(QOL). Consequently, it imposes a substantial economic and social burden on patients, families, and healthcare services[1,3]. Despite some contrary opinions, there is a widespread consensus that clozapine is the treatment of choice for patients with TRS[4,5]. However, even with optimal clozapine treatment, 40%-70% of the patients with TRS do not benefit from monotherapy with clozapine[6-9]. Patients with clozapine-resistant schizophrenia (CRS) are probably among the most severely ill of all patients with this disorder. A study comparing TRS and CRS found that the overall severity of the illness and positive and negative symptoms were significantly higher, while the QOL score was significantly lower among patients with CRS[10] Moreover, symptom severity among patients with CRS did not improve much over 6 mo of follow-up. Other estimates have suggested that apart from the greater symptom severity, patients with CRS are likely to be more frequent users of healthcare services and more likely to have multiple and prolonged hospitalizations[11].

Consequently, the cost of their care and the adverse impact of CRS on patients and their caregivers is also likely to be substantially greater than TRS[7,12]. Such serious consequences of CRS often compel clinicians to try new and different strategies to treat these patients. The option most commonly adopted is to add another psychotropic agent to clozapine to enhance its effects[9,11]. However, the evidence to date indicates that augmentation with medications or other treatments yields little or no additional benefits for these patients[13]. The treatment of CRS thus continues to pose a formidable challenge for clinicians. Moreover, the size of this group of patients will increase as the use of clozapine for TRS increases. Therefore, newer ways of managing CRS have to be explored. Accordingly, this review attempts to briefly summarize the research in this area, followed by a discussion of certain treatment options and strategies that appear promising.

**DEFINING AND CONCEPTUALIZING CRS**

The key elements of the current definitions of CRS are depicted in Table 1. These include a diagnosis of schizophrenia, moderate baseline severity, and non-response and persistence of symptoms, and functional impairment despite adequate treatment with clozapine[12,14-16]. Though these operationalized definitions of CRS represent an improvement, it is also apparent that the majority of clinical trials of patients with CRS have not utilized such definitions. Moreover, a major criticism of the current constructs of CRS is that they rely excessively on positive symptoms of schizophrenia[11,17,18]. Other domains such as negative, cognitive, or depressive symptoms, or QOL have not received sufficient attention. This gives rise to substantial heterogeneity in the CRS groups selected using such definitions, which further hinders research. Although measures such as more precise delineation of target symptoms and differentiating between “minimum and optimal criteria” required for CRS have been proposed[15,16], the current definitions are still far from perfect[11,15,18,19]. Finally, from a clinical perspective there are many practical difficulties in determining adequate doses, estimating blood levels, judging adherence, and conducting prospective observation of patients during treatment with clozapine[15,16].

**AUGMENTATION STRATEGIES FOR CRS: A BRIEF REVIEW**

***Medication augmentation***

In routine clinical practice, the commonest strategy to deal with CRS is augmentation with another antipsychotic[9,11,20,21]. Mood stabilizer or antidepressant augmentation is used less frequently. Some treatment guidelines also endorse augmentation with antipsychotics[13]. Over the past 25 years, many trials of clozapine augmentation with medications and other treatments have been conducted. Additionally, more than 50 reviews on the subject including narrative and systematic reviews, individual meta-analyses, and reviews of different meta-analyses have been published.

**Antipsychotic augmentation:** Some of the recent reviews of augmentation of clozapine with a second antipsychotic in CRS are included in Table 2[22-44].

Among all augmentation trials, the largest number has involved antipsychotic augmentation of clozapine non-response. Risperidone, aripiprazole, and amisulpride are the most commonly evaluated augmenting agents. Despite the size of the evidence, the majority of reviews have concluded that adding a second antipsychotic to clozapine does not have any significant impact on clinical response, overall symptom severity, or severity of positive symptoms[7,8,20,45,46]. Though some benefit has been noted when all trials are included, there appear to be no significant effects when only high-quality trials are considered[2,18]. Even when benefits are evident in well-designed randomized controlled trials (RCTs), the combined effect sizes are small to moderate casting doubts on the clinical significance of these findings. The effect of antipsychotic combinations with clozapine on negative and depressive symptoms has been examined less frequently. A similar inconsistency is apparent with some meta-analyses showing modest benefits, while others report no effects on these symptoms.

**Antidepressant and mood stabilizer augmentation:** As depicted in Table 3, the number of RCTs examining the augmentation of clozapine with antidepressants and mood stabilizers is comparatively less. Moreover, the trials are more often of poorer quality. Consequently, there is little evidence of the benefits of antidepressant augmentation on the severity of symptoms[23,24,30,37]. When some evidence of a positive effect has been found, it is usually based on single, high-quality RCTs[23,24,30,37]. Similarly, though mood stabilizer augmentation is reported to be beneficial in some meta-analyses[47,48], others have either found no benefit[7,24,46,49] or evidence of significant symptom reduction only in low-quality trials[2,8,23,30,50].

**Methodological lacunae:** One of the principal reasons for the inability to find effective medication augmentation options for CRS is the methodological shortcomings of current research. Even in the better quality RCTs, there is considerable heterogeneity in terms of the definitions used, the types and numbers of patients included, the duration of trials, and the outcomes examined. The methodological lacunae of the RCTs have in turn affected the methodological quality of meta-analytic examinations of the evidence. For example, in a systematic review of 21 meta-analyses only one was judged to have “very little risk of bias;” 7 had “low risk of bias,” and the rest had “high risk of bias”[2]. Therefore, there is considerable uncertainty even about the findings of meta-analytic studies.

***Augmentation with electroconvulsive therapy and recurrent transcranial magnetic stimulation***

Some of the more recent reviews have concluded that electroconvulsive therapy (ECT) is an effective augmentation strategy, especially when medications fail to decrease persistent positive symptoms[2,8,20,46,51]. However, this conclusion appears to be based on a single meta-analysis of 18 RCTs[52], which showed that the ECT-clozapine combination was better than clozapine alone in reducing positive symptoms. Then again, 17 of these RCTs were conducted in China and are not easily accessible[53]. As shown in Table 4, there are only two small RCTs of ECT augmentation of clozapine response. The first showed that the clozapine-ECT combination was more effective than clozapine alone in TRS[54], whereas the second did not find the combination to be more effective in CRS[55]. The rest of the evidence consists of non-randomized trials[56] and case studies. Thus, the higher response rates of the clozapine-ECT combination reported in systematic reviews[57-61] and other meta-analyses[62-64] are largely based on low-quality evidence, obtained mainly among patients with TRS, and limited to the short-term efficacy of ECT augmentation. Though the combination appears to be relatively safe, about 20% of the patients develop adverse effects, and there is some evidence of greater cognitive impairment[52,57,59,62,63]. Nevertheless, augmentation with ECT may result in a faster response, which is particularly useful among patients with high risks of aggression or self-harm[9,11,60,65]. Therefore, though the evidence is still inconclusive, the effects of ECT augmentation certainly merit further examination. On the other hand, augmentation with recurrent transcranial magnetic stimulation appears to be largely ineffective in CRS despite promising results from recent trials[66,67].

***Psychosocial augmentation strategies***

Two systematic reviews of psychosocial interventions have concluded that CBT can be effective among patients with poor response to clozapine[33,68]. As shown in Table 5, the evidence-base for CBT until recently had consisted of a few trials with small numbers and inadequate study designs[69-71] or RCTs that included some patients with CRS[72-74]. However, interest in the effects of CBT augmentation has been re-awakened with a large, well-designed RCT among patients with CRS[75]. This was the largest trial among all RCTs of clozapine augmentation. It employed standardized definitions of CRS and trained therapists who administered manual-based CBT to patients from routine clinical settings. After 9 mo of active treatment, the total Positive and Negative Symptom Scale scores, positive symptoms, emotional distress, and excitement had reduced significantly in the CBT group compared to the usual treatment group. However, at the end of 21 mo, there were no significant differences in the Positive and Negative Symptom Scale scores between the two groups, leading to the conclusion that CBT augmentation was not effective in CRS. Nevertheless, other indices suggested that CBT might be useful for a proportion of patients, and patients’ ratings of recovery were greater in the CBT group at 21 mo. Other noteworthy advantages of CBT were the high adherence rates, negligible adverse effects, high acceptability, and effect sizes comparable to medication augmentation. Therefore, others have interpreted these results differently to emphasize the positive effects of CBT augmentation[2,66,76]. Moreover, it has been pointed out that the persistence of positive effects beyond the active treatment period is not the best indicator of the efficacy of CBT[76]. Thus, if the standards for medication trials were to be applied to this RCT, the conclusion would be that CBT was an effective augmentation strategy for CRS after 9 mo of treatment.

**AUGMENTATION STRATEGIES FOR CRS: FROM EVIDENCE TO PRACTICE**

***Relying on clinical consensus***

This brief update of the existing literature shows that augmentation of clozapine response in CRS with medications, ECT, or CBT is largely ineffective. Any favourable outcome for augmentation is usually based on low-quality or limited evidence, and the clinical significance of the small effects obtained in some meta-analyses is unclear. Moreover, because of the inconsistent results and methodological uncertainties, the evidence offers no definite conclusions about the most effective augmentation strategies. Nevertheless, it has been suggested that the lack of evidence should not discourage clinicians from trying out these strategies in individual patients. This advice appears to be based on two assumptions. First, the lack of significant benefits applies only to entire groups of patients being evaluated in RCTs, whereas there may be considerable variability in individual responses of the patients comprising these groups[18,25,29,40]. Thus, there is a possibility that some patients may benefit from augmentation, though at present there is no way to identify these potential responders. Moreover, given the widespread adverse impact of CRS, even modest benefits are considered acceptable in clinical settings[7,22,46]. Therefore, the sequential use of different augmentation strategies is considered to be a realistic option in clinical practice.

To reduce the disparity between the evidence-based findings and clinical practice, researchers have been increasingly relying on clinical consensus to guide the management of complex and burdensome conditions such as CRS. A recent effort on these lines arrived at the following recommendations for augmentation of clozapine non-response: personalizing doses to reach plasma levels ≥ 350 ng/mL; a 3 mo trial for patients with positive symptoms; shorter treatment trials for those with violence or self-harm (2 mo) and longer periods (4 mo) for patients with negative or cognitive symptoms[13]. For persistent positive symptoms, adding aripiprazole, amisulpride, or ECT was suggested. Augmentation with antidepressants was recommended for negative symptoms while adding antidepressants, antipsychotics, mood stabilizers, or ECT to clozapine was proposed for CRS with increased risks of aggression or self-harm. Lastly, CBT or other psychosocial interventions were also felt to be useful. It was apparent that these clinicians were going beyond the current evidence while making some of these recommendations.

For example, though there is little support in the literature for augmentation of clozapine with a second antipsychotic, low-quality evidence or single RCTs have suggested that risperidone, aripiprazole, and amisulpride may be beneficial (Table 2). The group also relied on naturalistic studies showing that the clozapine-aripiprazole combination may have positive effects[77]. Similarly, for recommendations about antidepressants, positive evidence for antidepressant augmentation in schizophrenia was cited[78,79], though the evidence for similar effects of antidepressant augmentation in CRS is limited (Table 3).

Augmentation with mood stabilizers and ECT was recommended despite the acknowledgement that the evidence for these strategies is insufficient (Tables 3 and 4). The recommendation for using CBT if other treatments failed was based on the recent CBT trial[75], which concluded that certain individuals with CRS may benefit from a practical trial of CBT augmentation. Clozapine augmentation was preferred over a switch to a different antipsychotic because of the consistent evidence of adverse outcomes following cessation of clozapine[8,11,80-82]. Switching to high-dose olanzapine has been suggested as an alternative, but this option is not supported by evidence[81,83]. Finally, though most of the evidence indicates that these augmentation strategies are safe and well-tolerated[22,25,26,29], the possibility of new side effects arising during combined treatment could not be discounted[9,12,18,28,32]. Therefore, cautious monitoring of all patients for the duration of the augmentation trial was also recommended.

***Trying newer options for augmentation***

**Augmentation with long-acting antipsychotic injections:** Apart from problems of resistance, non-adherence is a major hindrance to effective treatment with clozapine. Although non-adherence with clozapine may be lower than other antipsychotics, rates of intentional non-adherence vary from 23%-55% during treatment[84-88]. In such situations initiating a long-acting antipsychotic injection (LAI) remains the only option[89]. Intramuscular clozapine appears to have some benefits in enhancing adherence, but it has not been used frequently[90,91]. Recent studies suggest that apart from reducing non-adherence, LAI augmentation of clozapine may also have a role in enhancing clozapine response in CRS. As shown in Table 6, this evidence is still preliminary and consists mostly of series of patients and observational studies[92-102]. However, mirror-image studies that are considered the current standard for evaluating LAI efficacy[103,104] have also been conducted. Taken together, this body of evidence suggests that the combination of clozapine with LAIs leads to a reduction in all types of symptoms and behavioural problems such as aggression and suicidality as well as improvements in social functioning. The lowered risk of relapses and reduction in the number and length of hospitalizations has also been replicated consistently. Lastly, it appears that lower doses of both medications are required, while side effects are either less, or no more common with the combination than with clozapine monotherapy.

Indirect evidence for the effectiveness of clozapine-LAI combinations also comes from several Scandinavian nationwide cohort studies of antipsychotic treatment summarized in Table 7[77,82,105-109]. These provide the strongest support for the notion that clozapine and LAIs are the two most effective treatments for patients with both first episode and chronic schizophrenia. Incidentally, some of these studies have also shown that the combination of clozapine and aripiprazole is more effective than clozapine monotherapy[77]. Therefore, the combination of clozapine and LAIs appears to be a promising option that needs to be examined further for its usefulness in the management of CRS.

**A re-evaluation of psychosocial augmentation strategies:** Although the evidence reviewed in Table 5 suggests that augmentation with CBT does not yield consistent benefits in CRS, there are several reasons to re-examine the usefulness of psychosocial augmentation strategies. To begin with, CBT augmentation appears to be effective for persistent positive symptoms in TRS[20,68,75,76]. Moreover, the largest and most meticulously conducted CBT trial has shown a small but significant benefit for patients with CRS following the active intervention phase[66,75,76]. The same trial has suggested that CBT is one of the safest and acceptable augmentation options for patients with CRS. The evidence from this study and other trials shows that CBT augmentation has added benefits such as improvements in socio-occupational functioning and QOL. Moreover, symptomatic remission appears to be faster with CBT augmentation, and the benefits obtained may persist longer[71,72,74]. CBT augmentation early in the course of clozapine treatment may further enhance its benefits[68-70,74].

Further, it has been proposed that rather than using only CBT, multi-component psychosocial interventions using different techniques might be more effective in enhancing clozapine response[33,110,111]. Though CBT is the most common psychosocial treatment used in patients with TRS, there is evidence to suggest that other types of interventions might be equally effective[68,112]. Psychoeducation and family interventions are also effective for schizophrenia[113], but they have not been tried out as augmenting strategies in TRS or CRS[20,68]. Lastly, psychosocial augmentation might be useful in other ways, for example in improving adherence to clozapine. An RCT that compared CBT with psychoeducation among patients with TRS on clozapine showed that both treatments led to improvements in patient empowerment, treatment alliance, and medication persistence[114]. Thus, while there may be no compelling evidence in favour of psychosocial augmentation strategies in CRS, there is scope for further evaluation of these potentially useful treatments.

**PREVENTING RESISTANCE TO CLOZAPINE TREATMENT**

The relative ineffectiveness of the different augmentation strategies suggests that a more fruitful option could be to try and prevent resistance to clozapine treatment from developing.

***Predicting clozapine resistance***

Predicting who among patients with TRS will not respond adequately to clozapine may be helpful because augmentation strategies could be instituted early in such patients to mitigate the adverse effects of clozapine resistance. However, despite over 300 studies of prediction of clozapine response, consistent predictors of response have not been found. Some reviews have concluded that there are no reliable predictors of clozapine response because of the inconsistent results and methodological uncertainties of existing research[115,116]. On the other hand, an older systematic review and a more recent meta-analysis have found that older age, greater severity of symptoms, especially negative symptom severity, poorer functioning, and non-paranoid subtypes could predict clozapine non-response[117,118]. Low cerebrospinal homovanillicacid to 5-hydroxyindoleacetic acid ratios and normal structure and function of the prefrontal cortex have also emerged as reliable predictors of good response in some studies[117,119]. Consequently, because of the inconclusive nature of this evidence, currently the only way to predict clozapine resistance is to carry out an adequate trial of clozapine treatment under optimal conditions[20,115].

***Optimizing clozapine treatment***

Ensuring adequate treatment with clozapine may thus be the best option to prevent clozapine resistance. The necessary steps for optimizing clozapine treatment are listed in Table 8. Personalized dosing is a key component because of the wide variations in dose-blood level ratios between individuals and because many patients respond at lower doses[120,121].

Data on gender differences in clozapine treatment are scarce, and results are often inconsistent[122]. This is particularly true for response to clozapine treatment. Though the response is usually poorer in women[116,117,122], research on clozapine’s effectiveness has also found better outcomes among women, although these differences in their favour are often of doubtful clinical significance[115,117,123]. Others have found no differences in outcome between the two genders[118].

In contrast, differences in pharmacokinetics are reported more consistently[122,124,125]. Women have lower renal clearance of clozapine than men because of differences in the activity of cytochrome P450 enzymes such as CYP1A2. Most studies have found higher plasma levels of clozapine in women, and some have also found higher levels of its metabolite norclozapine. Higher dose-blood level ratios have also been found in women. Therefore, women usually require lower doses of clozapine[124]. These pharmacokinetic differences also increase the risk of dose-dependent side effects in women, particularly metabolic side effects[122,126]. Accordingly, most of the evidence on gender differences in side effects of clozapine relates to metabolic disturbances[122]. However, findings are not consistent, and both genders appear to have increased risk of metabolic syndrome in different reports[122,126-128]. Hypertension, elevated triglycerides, lower high-density lipoprotein levels, and cardiac abnormalities appear to be more common in men[122]. Women are more likely to develop hyperglycaemia and diabetes and increases in weight and body mass index[122,126]. There is very little evidence of gender differences in other side effects, though certain studies have found haematological abnormalities and constipation to be commoner among women[122,125,128,129].

Unlike the influence of gender, ethnicity does not appear to have any impact on treatment response obtained with clozapine[115,130]. On the other hand, there are ethnic differences in pharmacokinetic profiles of clozapine[122]. More specifically, several studies among Asian patients have consistently indicated that they require about half the standard dose of clozapine due to their lowered clozapine metabolism[131-135]. The dose of clozapine required for adequate response among Asians varies from 150mg/d among women to 300 mg/d for men who smoke. Therefore, Asian patients need lower doses at the start of treatment and slower upward titration to reach their optimum dose. Despite these pharmacokinetic dissimilarities, ethnic differences seem to have minimal impact on the prevalence of adverse effects of clozapine[129]. Nevertheless, non-White ethnicity is a risk factor for metabolic syndrome, and certain studies have found a higher prevalence of hypertension and weight gain in Asians[127,136]. Others have found a higher risk of agranulocytosis in Asian patients[137]. This again emphasizes the fact that the best way to individualize clozapine doses is to base them on blood levels. Doing so has the added advantages of lessening side effects and allowing adherence to be monitored. However, facilities for blood levels are not always available. Standardized dosing schedules could be used in such instances[132].

Many of the side effects encountered with clozapine are dose-dependent including sedation, tachycardia, hypersalivation, enuresis, constipation, delirium, obsessive-compulsive symptoms, seizures, and orthostatic hypotension[81,120,138] Among all antipsychotics, the prevalence of metabolic dysfunction or metabolic syndrome is the highest for clozapine and olanzapine[81,126,127,132,139]. Whether metabolic side effects are also dose-dependent is not clear[81,138]. However, systematic reviews and meta-analyses have indicated a dose-outcome association between clozapine and metabolic side effects, particularly with lipid levels and weight gain[140,141]. Risk factors for metabolic syndrome include higher baseline weight or body mass index, gender, non-White, possibly Asian ethnicity, and several genetic and peptide markers[126,127,136,139,142]. Somewhat paradoxically, metabolic disturbances are also associated with a reduction in symptoms[126,127].

Optimizing clozapine doses is the principal way of managing most dose-dependent side effects. Using the lowest effective dose, slow increase in doses, and dose adjustments to minimize side effects is always recommended[81,120,123]. Discontinuation of concomitant medications that might not be essential also reduces the side effect burden[120]. Only serious and life-threatening adverse reactions such as agranulocytosis and some cardiopulmonary complications require abrupt discontinuation of clozapine[81,120]. Some side effects such as neuroleptic malignant syndrome, thromboembolism, or diabetic ketoacidosis may require temporary discontinuation followed by re-initiation of clozapine[81]. In most other situations, the dose of clozapine should be reduced very gradually to avoid worsening of clinical state or emergence of withdrawal symptoms[120]. When side effects persist despite optimizing the dose of clozapine, the options include adding other medications, instituting non-pharmacological measures to manage side effects, or combining clozapine with another antipsychotic[120,138]. In the case of metabolic syndrome, adequate treatment of risk factors and metabolic derangements is essential[143].

Meta-analyses of interventions for metabolic side effects have shown that adjunctive metformin is the most effective strategy[144,145]. Behavioural weight management strategies are also recommended though the evidence for their efficacy is uncertain[120,138,144]. Adding aripiprazole to clozapine to reduce both the clozapine dose and metabolic disturbances has also been suggested, but the evidence for this option is limited[120,144].

Minimizing the side effect burden is necessary because about 40% of the patients (range 21%-67%) stop taking clozapine in the first few years of treatment[82,84,86,87,146]. In 20%-30% of them, discontinuation is because of intolerable side effects, though intentional non-adherence appears to be somewhat more common[84,85,87,88,147]. Managing non-adherence requires open and non-judgmental discussions about medication-taking with patients, monitoring of adherence based on all available methods including caregiver reports, education to deal with misconceptions about treatment, and building trusting alliances with patients and families to ensure continued treatment. A collaboration with the patient and the family is an essential part of optimizing clozapine treatment that is often overlooked[65,110,111,120]. Shared decision-making about treatment, education, stress-management, support, and involvement of caregivers are ways of ensuring truly collaborative alliances.

Lastly, increasing evidence indicates substantial underutilization and delayed use of clozapine[148,149]. Clinician’s lack of awareness and experience with clozapine, their misplaced concerns about its use, and the discrepancy between clinicians’ and patients’ attitudes regarding clozapine are among the main causes of inappropriate use of clozapine[150,151]. Therefore, dealing with these clinician-related barriers is also necessary to ensure the proper use of clozapine.

**CONCLUSION**

Clozapine resistance is probably one of the most difficult conditions that clinicians treating patients with schizophrenia are likely to encounter. Unfortunately, the existing research evidence does not provide any firm guidelines about treatment options once clozapine fails. However, because of the seriousness of the condition and the widespread negative impact of CRS, clinicians need to look beyond the evidence and rely on consensus-based recommendations. At present, effective ways to deal with CRS are to optimize clozapine treatment, choose among the best available options judiciously, explore newer ways of augmentation, and adopt a holistic approach to treatment that includes simple psychosocial measures in addition to pharmacological ones. Finally, cautious optimism, commitment to treatment, patience, and persistence from clinicians, patients, and caregivers are almost always required for the effective use of clozapine.

**REFERENCES**

1 **Kane JM**, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, Olfson M, Potkin SG, Correll CU. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. *J Clin Psychiatry* 2019; **80** [PMID: 30840788 DOI: 10.4088/JCP.18com12123]

2 **Wagner E**, Löhrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. *J Psychopharmacol* 2019; **33**: 423-435 [PMID: 30696332 DOI: 10.1177/0269881118822171]

3 **Kennedy JL**, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. *Int Clin Psychopharmacol* 2014; **29**: 63-76 [PMID: 23995856 DOI: 10.1097/YIC.0b013e32836508e6]

4 **Taylor DM**. Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard? *CNS Drugs* 2017; **31**: 177-180 [PMID: 28258419 DOI: 10.1007/s40263-017-0411-6]

5 **Faden J**. Treatment-Resistant Schizophrenia: A Brief Overview of Treatment Options. *J Clin Psychiatry* 2019; **80** [PMID: 30900848 DOI: 10.4088/JCP.18ac12394]

6 **Siskind D**, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. *Can J Psychiatry* 2017; **62**: 772-777 [PMID: 28655284 DOI: 10.1177/0706743717718167]

7 **De Berardis D**, Fornaro M, Anastasia A, Vellante F, Valchera A, Cavuto M, Perna G, Di Nicola M, Serafini G, Carano A, Pompili M, Orsolini L, Tomasetti C, Di Emidio G, Martinotti G, Di Giannantonio M. When clozapine fails: Augmentation strategies in the management of clozapine-resistant schizophrenia. In: Kim YK. Treatment resistance in psychiatry. Risk factors, biology, and management. Singapore: Springer Nature Singapore Pte Ltd, 2019: 349-367 [DOI: 10.1007/978-981-10-4358-1\_23]

8 **Roerig JL**. Clozapine augmentation strategies. *Ment Health Clin* 2019; **9**: 336-348 [PMID: 31857930 DOI: 10.9740/mhc.2019.11.336]

9 **Muscatello MR**, Bruno A, De Fazio P, Segura-Garcia C, Pandolfo G, Zoccali R. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. *Expert Opin Pharmacother* 2014; **15**: 2329-2345 [PMID: 25284216 DOI: 10.1517/14656566.2014.956082]

10 **Henna Neto J**, Elkis H. Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study. *Braz J Psychiatry* 2007; **29**: 228-232 [PMID: 17891260 DOI: 10.1590/S1516-44462007000300007]

11 **Buckley P**, Miller A, Olsen J, Garver D, Miller DD, Csernansky J. When symptoms persist: clozapine augmentation strategies. *Schizophr Bull* 2001; **27**: 615-628 [PMID: 11824488 DOI: 10.1093/oxfordjournals.schbul.a006901]

12 **Tranulis C**, Mouaffak F, Chouchana L, Stip E, Gourevitch R, Poirier MF, Olié JP, Lôo H, Gourion D. Somatic augmentation strategies in clozapine resistance--what facts? *Clin Neuropharmacol* 2006; **29**: 34-44 [PMID: 16518133 DOI: 10.1097/00002826-200601000-00010]

13 **Wagner E**, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, Lee J, Falkai P, Schneider-Axmann T, Hasan A; TRRIP Working Group. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. *Schizophr Bull* 2020; **46**: 1459-1470 [PMID: 32421188 DOI: 10.1093/schbul/sbaa060]

14 **Mouaffak F**, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olié JP, Lôo H, Gourion D. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. *Clin Neuropharmacol* 2006; **29**: 28-33 [PMID: 16518132 DOI: 10.1097/00002826-200601000-00009]

15 **Lee J**, Takeuchi H, Fervaha G, Sin GL, Foussias G, Agid O, Farooq S, Remington G. Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. *Can J Psychiatry* 2015; **60**: 515-522 [PMID: 26720509 DOI: 10.1177/070674371506001107]

16 **Howes OD**, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. *Am J Psychiatry* 2017; **174**: 216-229 [PMID: 27919182 DOI: 10.1176/appi.ajp.2016.16050503]

17 **Paton C**, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. *J Clin Psychopharmacol* 2007; **27**: 198-204 [PMID: 17414246 DOI: 10.1097/JCP.0b013e318036bfbb]

18 **Castle DJ**, Keks N. What can we do if clozapine fails? Pharmacologic choices and differential outcomes. In: Buckley PF, Gaughran F. Treatment-refractory schizophrenia. Heidelberg: Springer-Verlag Berlin, 2014: 93-106 [DOI: 10.1007/978-3-642-45257-4\_7]

19 **Farooq S**, Agid O, Foussias G, Remington G. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. *Schizophr Bull* 2013; **39**: 1169-1172 [PMID: 24045038 DOI: 10.1093/schbul/sbt137]

20 **Lally J**, Gaughran F. Treatment resistant schizophrenia - review and a call to action. *Ir J Psychol Med* 2019; **36**: 279-291 [PMID: 30477599 DOI: 10.1017/ipm.2018.47]

21 **Pai NB**, Laidlaw M, Vella SC. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'. *Acta Psychiatr Scand* 2012; **126**: 40-46 [PMID: 22432694 DOI: 10.1111/j.1600-0447.2012.01854.x]

22 **Bartoli F**, Crocamo C, Di Brita C, Esposito G, Tabacchi TI, Verrengia E, Clerici M, Carrà G. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis. *J Psychiatr Res* 2019; **108**: 24-33 [PMID: 30447508 DOI: 10.1016/j.jpsychires.2018.11.005]

23 **Siskind DJ**, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, Kisely S. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. *Aust N Z J Psychiatry* 2018; **52**: 751-767 [PMID: 29732913 DOI: 10.1177/0004867418772351]

24 **Correll CU**, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. *JAMA Psychiatry* 2017; **74**: 675-684 [PMID: 28514486 DOI: 10.1001/jamapsychiatry.2017.0624]

25 **Galling B**, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. *World Psychiatry* 2017; **16**: 77-89 [PMID: 28127934 DOI: 10.1002/wps.20387]

26 **Ortiz-Orendain J**, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams CE. Antipsychotic combinations for schizophrenia. *Cochrane Database Syst Rev* 2017; **6**: CD009005 [PMID: 28658515 DOI: 10.1002/14651858.CD009005.pub2]

27 **Barber S**, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. *Cochrane Database Syst Rev* 2017; **3**: CD006324 [PMID: 28333365 DOI: 10.1002/14651858.CD006324.pub3]

28 **Jiménez-Cornejo M**, Munizaga G, Aceituno D. Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia? *Medwave* 2016; **16**: e6614 [PMID: 27922589 DOI: 10.5867/medwave.2016.6614]

29 **Taylor DM**, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. *Acta Psychiatr Scand* 2012; **125**: 15-24 [PMID: 22077319 DOI: 10.1111/j.1600-0447.2011.01792.x]

30 **Sommer IE**, Begemann MJ, Temmerman A, Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. *Schizophr Bull* 2012; **38**: 1003-1011 [PMID: 21422107 DOI: 10.1093/schbul/sbr004]

31 **Porcelli S**, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. *Eur Neuropsychopharmacol* 2012; **22**: 165-182 [PMID: 21906915 DOI: 10.1016/j.euroneuro.2011.08.005]

32 **Chong SA**, Remington G. Clozapine augmentation: safety and efficacy. *Schizophr Bull* 2000; **26**: 421-440 [PMID: 10885641 DOI: 10.1093/oxfordjournals.schbul.a033463]

33 **Ranasinghe I**, Sin J.A systematic review of evidence-based treatment for individuals with treatment-resistant schizophrenia and a suboptimal response to clozapine monotherapy. *Psychosis* 2014; **6**: 253-265 [DOI: 10.1080/17522439.2013.830319]

34 **Barbui C**, Signoretti A, Mulè S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? *Schizophr Bull* 2009; **35**: 458-468 [PMID: 18436527 DOI: 10.1093/schbul/sbn030]

35 **Cipriani A**, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. *Cochrane Database Syst Rev* 2009: CD006324 [PMID: 19588385 DOI: 10.1002/14651858.CD006324.pub2]

36 **Correll CU**, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. *Schizophr Bull* 2009; **35**: 443-457 [PMID: 18417466 DOI: 10.1093/schbul/sbn018]

37 **Veerman SR**, Schulte PF, Begemann MJ, de Haan L. Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. *Pharmacopsychiatry* 2014; **47**: 231-238 [PMID: 25121994 DOI: 10.1055/s-0034-1385930]

38 **National Collaborating Centre for Mental Health (UK)**. Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014. London: National Institute for Health and Care Excellence (UK); 2014 [PMID: 25340235]

39 **Kontaxakis VP**, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. *Eur Psychiatry* 2005; **20**: 409-415 [PMID: 16171655 DOI: 10.1016/j.eurpsy.2004.12.007]

40 **Taylor DM**, Smith L. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies. *Acta Psychiatr Scand* 2009; **119**: 419-425 [PMID: 19245679 DOI: 10.1111/j.1600-0447.2009.01367.x]

41 **Li YY**, Zhang YS, Wang J, Li KQ, Wang HY. Optimal Treatment Strategies of Clozapine for Refractory Schizophrenia. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 2016; **38**: 666-678 [PMID: 28065233 DOI: 10.3881/j.issn.1000-503X.2016.06.008]

42 **Rolph L**, McGarry K. Combination of clozapine with an atypical antipsychotic: a meta-analysis. *Ment Health Rev (Brighton)* 2017; **22**: 277-288 [DOI:10.1108/MHRJ-01-2017-0001]

43 **Srisurapanont M**, Suttajit S, Maneeton N, Maneeton B. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. *J Psychiatr Res* 2015; **62**: 38-47 [PMID: 25619176 DOI: 10.1016/j.jpsychires.2015.01.004]

44 **Wang J**, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. *Cochrane Database Syst Rev* 2010: CD008125 [PMID: 20091661 DOI: 10.1002/14651858.CD008125.pub2]

45 **Faden J**, Citrome L. Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment. *Expert Opin Pharmacother* 2019; **20**: 11-24 [PMID: 30407873 DOI: 10.1080/14656566.2018.1543409]

46 **Miyamoto S**, Jarskog LF, Fleischhacker WW. Schizophrenia: when clozapine fails. *Curr Opin Psychiatry* 2015; **28**: 243-248 [PMID: 25768082 DOI: 10.1097/YCO.0000000000000159]

47 **Tiihonen J**, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2009; **109**: 10-14 [PMID: 19186030 DOI: 10.1016/j.schres.2009.01.002]

48 **Zheng W**, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HF, Correll CU. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. *Acta Psychiatr Scand* 2016; **134**: 385-398 [PMID: 27585549 DOI: 10.1111/acps.12631]

49 **Veerman SR**, Schulte PF, Begemann MJ, Engelsbel F, de Haan L. Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. *Pharmacopsychiatry* 2014; **47**: 185-194 [PMID: 25002291 DOI: 10.1055/s-0034-1383656]

50 **Zheng W**, Xiang YT, Yang XH, Xiang YQ, de Leon J. Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials. *J Clin Psychiatry* 2017; **78**: e498-e505 [PMID: 28355041 DOI: 10.4088/JCP.16r10782]

51 **Gałaszkiewicz J**, Rębisz K, Morylowska-Topolska J, Karakuła-Juchnowicz H, Kozak G. Clozapine-resistant schizophrenia – non pharmacological augmentation methods. *CurrProblPsychiatr*2017; **18**: 279-291 [DOI: 10.1515/cpp-2017-0021]

52 **Wang G**, Zheng W, Li XB, Wang SB, Cai DB, Yang XH, Ungvari GS, Xiang YT, Correll CU. ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. *J Psychiatr Res* 2018; **105**: 23-32 [PMID: 30144667 DOI: 10.1016/j.jpsychires.2018.08.002]

53 **Lal S**, Suetani S, Pant M, Parker S. Treating difficult-to-treat psychosis: Comments on Siskind et al. (2018). *Aust N Z J Psychiatry* 2018; **52**: 1215 [PMID: 30387361 DOI: 10.1177/0004867418808898]

54 **Petrides G**, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, Kane JM, Sanghani S, Goldberg TE, John M, Mendelowitz A. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. *Am J Psychiatry* 2015; **172**: 52-58 [PMID: 25157964 DOI: 10.1176/appi.ajp.2014.13060787]

55 **Melzer-Ribeiro DL**, Paulo RS, Kayo M, Avrichir BS, Ribeiro RB, Santos BD, Fortes M, Elkis H. Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT – sham controlled trial. *Arch Clin Psychiatry (São Paulo)* 2017; **44**: 45-50 [DOI: 10.1590/0101-60830000000116]

56 **Masoudzadeh A**, Khalilian AR. Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. *Pak J Biol Sci* 2007; **10**: 4287-4290 [PMID: 19086588 DOI: 10.3923/pjbs.2007.4287.4290]

57 **Kupchik M**, Spivak B, Mester R, Reznik I, Gonen N, Weizman A, Kotler M. Combined electroconvulsive-clozapine therapy. *Clin Neuropharmacol* 2000; **23**: 14-16 [PMID: 10682225 DOI: 10.1097/00002826-200001000-00003]

58 **Braga RJ**, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. *J ECT* 2005; **21**: 75-83 [PMID: 15905747 DOI: 10.1097/01.yct.0000165500.60784.05]

59 **Havaki-Kontaxaki BJ**, Ferentinos PP, Kontaxakis VP, Paplos KG, Soldatos CR. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. *Clin Neuropharmacol* 2006; **29**: 52-56 [PMID: 16518135 DOI: 10.1097/00002826-200601000-00012]

60 **Pompili M**, Lester D, Dominici G, Longo L, Marconi G, Forte A, Serafini G, Amore M, Girardi P. Indications for electroconvulsive treatment in schizophrenia: a systematic review. *Schizophr Res* 2013; **146**: 1-9 [PMID: 23499244 DOI: 10.1016/j.schres.2013.02.005]

61 **Grover S**, Hazari N, Kate N. Combined use of clozapine and ECT: a review. *Acta Neuropsychiatr* 2015; **27**: 131-142 [PMID: 25697225 DOI: 10.1017/neu.2015.8]

62 **Lally J**, Tully J, Robertson D, Stubbs B, Gaughran F, MacCabe JH. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. *Schizophr Res* 2016; **171**: 215-224 [PMID: 26827129 DOI: 10.1016/j.schres.2016.01.024]

63 **Kittsteiner Manubens L**, Lobos Urbina D, Aceituno D. Is electroconvulsive therapy effective as augmentation in clozapine-resistant schizophrenia? *Medwave* 2016; **16**: e6577 [PMID: 27813505 DOI: 10.5867/medwave.2016.6577]

64 **Ahmed S**, Khan AM, Mekala HM, Venigalla H, Ahmed R, Etman A, Esang M, Qureshi M. Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis. *Heliyon* 2017; **3**: e00429 [PMID: 29264404 DOI: 10.1016/j.heliyon.2017.e00429]

65 **Barnes TR**, McEvedy CJ, Nelson HE. Management of treatment resistant schizophrenia unresponsive to clozapine. *Br J Psychiatry Suppl* 1996: 31-40 [PMID: 8968653 DOI: 10.1192/S0007125000298590]

66 **Wagner E**, Honer WG, Sommer IE, Koops S, Blumberger DM, Daskalakis ZJ, Dlabac-De Lange JJ, Bais L, Knegtering H, Aleman A, Novak T, Klirova M, Slotema C, Brunelin J, Poulet E, Kujovic M, Cordes J, Wobrock T, Siskind D, Falkai P, Schneider-Axmann T, Hasan A. Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine. *World J Biol Psychiatry* 2021; **22**: 14-26 [PMID: 32081071 DOI: 10.1080/15622975.2020.1733080]

67 **Wagner E**, Wobrock T, Kunze B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wölwer W, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Siskind D, Malchow B, Strube W, Schneider-Axmann T, Falkai P, Hasan A. Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. *Schizophr Res* 2019; **208**: 370-376 [PMID: 30704862 DOI: 10.1016/j.schres.2019.01.021]

68 **Polese D**, Fornaro M, Palermo M, De Luca V, de Bartolomeis A. Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis. *Front Psychiatry* 2019; **10**: 210 [PMID: 31057434 DOI: 10.3389/fpsyt.2019.00210]

69 **Pinto A**, La Pia S, Mennella R, Giorgio D, DeSimone L. Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. *Psychiatr Serv* 1999; **50**: 901-904 [PMID: 10402608 DOI: 10.1176/ps.50.7.901]

70 **Buchain PC**, Vizzotto AD, Henna Neto J, Elkis H. Randomized controlled trial of occupational therapy in patients with treatment-resistant schizophrenia. *Braz J Psychiatry* 2003; **25**: 26-30 [PMID: 12975676 DOI: 10.1590/s1516-44462003000100006]

71 **Barretto EM**, Kayo M, Avrichir BS, Sa AR, Camargo Md, Napolitano IC, Nery FG, Pinto JA Jr, Bannwart S, Scemes S, Di Sarno E, Elkis H. A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia. *J Nerv Ment Dis* 2009; **197**: 865-868 [PMID: 19996727 DOI: 10.1097/NMD.0b013e3181be7422]

72 **Sensky T**, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, O'Carroll M, Barnes TR. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. *Arch Gen Psychiatry* 2000; **57**: 165-172 [PMID: 10665619 DOI: 10.1001/archpsyc.57.2.165]

73 **Valmaggia LR**, van der Gaag M, Tarrier N, Pijnenborg M, Slooff CJ. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. *Br J Psychiatry* 2005; **186**: 324-330 [PMID: 15802690 DOI: 10.1192/bjp.186.4.324]

74 **Edwards J**, Cocks J, Burnett P, Maud D, Wong L, Yuen HP, Harrigan SM, Herrman-Doig T, Murphy B, Wade D, McGorry PD. Randomized Controlled Trial of Clozapine and CBT for First-Episode Psychosis with Enduring Positive Symptoms: A Pilot Study. *Schizophr Res Treatment* 2011; **2011**: 394896 [PMID: 22937265 DOI: 10.1155/2011/394896]

75 **Morrison AP**, Pyle M, Gumley A, Schwannauer M, Turkington D, MacLennan G, Norrie J, Hudson J, Bowe SE, French P, Byrne R, Syrett S, Dudley R, McLeod HJ, Griffiths H, Barnes TRE, Davies L, Kingdon D; FOCUS trial group. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. *Lancet Psychiatry* 2018; **5**: 633-643 [PMID: 30001930 DOI: 10.1016/S2215-0366(18)30184-6]

76 **Schooler NR**. Cognitive behavioural therapy for clozapine non-responders. *Lancet Psychiatry* 2018; **5**: 607-608 [PMID: 30001931 DOI: 10.1016/S2215-0366(18)30256-6]

77 **Tiihonen J**, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. *JAMA Psychiatry* 2019; **76**: 499-507 [PMID: 30785608 DOI: 10.1001/jamapsychiatry.2018.4320]

78 **Galling B**, Vernon JA, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, Tsoy-Podosenin M, Poyurovsky M, Kane JM, Correll CU. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. *Acta Psychiatr Scand* 2018; **137**: 187-205 [PMID: 29431197 DOI: 10.1111/acps.12854]

79 **Helfer B**, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, Engel RR, Leucht S. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. *Am J Psychiatry* 2016; **173**: 876-886 [PMID: 27282362 DOI: 10.1176/appi.ajp.2016.15081035]

80 **Remington G**, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. *CNS Drugs* 2005; **19**: 843-872 [PMID: 16185094 DOI: 10.2165/00023210-200519100-00004]

81 **Nielsen J**, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? *J Clin Psychiatry* 2013; **74**: 603-13; quiz 613 [PMID: 23842012 DOI: 10.4088/JCP.12r08064]

82 **Luykx JJ**, Stam N, Tanskanen A, Tiihonen J, Taipale H. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. *Br J Psychiatry* 2020; **217**: 498-505 [PMID: 31910911 DOI: 10.1192/bjp.2019.267]

83 **Elkis H**, Meltzer HY. [Refractory schizophrenia]. *Braz J Psychiatry* 2007; **29 Suppl 2**: S41-S47 [PMID: 18157433 DOI: 10.1590/s1516-44462007000600002]

84 **Davis MC**, Fuller MA, Strauss ME, Konicki PE, Jaskiw GE. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. *Acta Psychiatr Scand* 2014; **130**: 30-39 [PMID: 24299466 DOI: 10.1111/acps.12233]

85 **Krivoy A**, Malka L, Fischel T, Weizman A, Valevski A. Predictors of clozapine discontinuation in patients with schizophrenia. *Int Clin Psychopharmacol* 2011; **26**: 311-315 [PMID: 21849905 DOI: 10.1097/YIC.0b013e32834ab34c]

86 **Legge SE**, Hamshere M, Hayes RD, Downs J, O'Donovan MC, Owen MJ, Walters JTR, MacCabe JH. Reasons for discontinuing clozapine: A cohort study of patients commencing treatment. *Schizophr Res* 2016; **174**: 113-119 [PMID: 27211516 DOI: 10.1016/j.schres.2016.05.002]

87 **Pai NB**, Vella SC. Reason for clozapine cessation. *Acta Psychiatr Scand* 2012; **125**: 39-44 [PMID: 22017729 DOI: 10.1111/j.1600-0447.2011.01776.x]

88 **Taylor DM**, Douglas-Hall P, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. *Br J Psychiatry* 2009; **194**: 165-167 [PMID: 19182180 DOI: 10.1192/bjp.bp.108.051979]

89 Mortimer A. Using clozapine in clinical practice. *Adv Psychiatr Treat* 2011; **17**: 256-265 [DOI: 10.1192/apt.bp.110.008136]

90 **Henry R**, Massey R, Morgan K, Deeks J, Macfarlane H, Holmes N, Silva E. Evaluation of the effectiveness and acceptability of intramuscular clozapine injection: illustrative case series. *BJPsych Bull* 2020; **44**: 239-243 [PMID: 32081110 DOI: 10.1192/bjb.2020.6]

91 **Casetta C**, Oloyede E, Whiskey E, Taylor DM, Gaughran F, Shergill SS, Onwumere J, Segev A, Dzahini O, Legge SE, MacCabe JH. A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis. *Br J Psychiatry* 2020; **217**: 506-513 [PMID: 32605667 DOI: 10.1192/bjp.2020.115]

92 **Se Hyun Kim**, Dong Chung Jung, Yong Min Ahn, Yong Sik Kim. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. *J Psychopharmacol* 2010; **24**: 981-986 [PMID: 19942641 DOI: 10.1177/0269881109348174]

93 **Malla A**, Tibbo P, Chue P, Levy E, Manchanda R, Teehan M, Williams R, Iyer S, Roy MA. Long-acting injectable antipsychotics: recommendations for clinicians. *Can J Psychiatry* 2013; **58**: 30S-35S [PMID: 23945065 DOI: 10.1177/088740341305805s05]

94 **Baruch N**, Das M, Sharda A, Basu A, Bajorek T, Ross CC, Sengupta S, Larkin F, Young S. An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital. *Ther Adv Psychopharmacol* 2014; **4**: 186-192 [PMID: 25360243 DOI: 10.1177/2045125314531982]

95 **Maia-de-Oliveira JP**, Nunes EA, Ushirohira JM, Machado-de-Sousa JP, Bressan RA, Hallak JE. Paliperidone palmitate for refractory and clozapine-resistant schizophrenia. *J Neuropsychiatry Clin Neurosci* 2015; **27**: e14-e16 [PMID: 25716490 DOI: 10.1176/appi.neuropsych.13120374]

96 **Kasinathan J**, Sharp G, Barker A. Evaluation of olanzapine pamoate depot in seriously violent males with schizophrenia in the community. *Ther Adv Psychopharmacol* 2016; **6**: 301-307 [PMID: 27721969 DOI: 10.1177/2045125316656319]

97 **Sepede G**, Di Iorio G, Spano MC, Lorusso M, Sarchione F, Santacroce R, Salerno RM, Di Giannantonio M. A Case of Resistant Schizophrenia Successfully Treated With Clozapine/Long-acting Injectable Aripiprazole Combination. *Clin Neuropharmacol* 2016; **39**: 322-324 [PMID: 27764052 DOI: 10.1097/WNF.0000000000000191]

98 **Oriolo G**, Dominguez I, Fortea A, Bioque M, Bernardo M, Parellada. Combination of clozapine with paliperidone in treatment resistant schizophrenia. *Eurneuropsychopharmacol* 2016; **26**: S536 [DOI: 10.1016/S0924-977X(16)31574-7]

99 **Souaiby L**, Gauthier C, Rieu C, Krebs MO, Advenier-Iakovlev E, Gaillard R. Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study. *Schizophr Res* 2017; **188**: 89-91 [PMID: 28139358 DOI: 10.1016/j.schres.2017.01.036]

100 **Grimminck R**, Oluboka O, Sihota M, Rutherford DL, Yeung H. Combination of Clozapine With Long-Acting Injectable Antipsychotics in Treatment-Resistant Schizophrenia: Preliminary Evidence From Health Care Utilization Indices. *Prim Care Companion CNS Disord* 2020; **22** [PMID: 32678523 DOI: 10.4088/PCC.19m02560]

101 **Bioque M**, Parellada E, García-Rizo C, Amoretti S, Fortea A, Oriolo G, Palau P, Boix-Quintana E, Safont G, Bernardo M. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. *Eur Psychiatry* 2020; **63**: e71 [PMID: 32669145 DOI: 10.1192/j.eurpsy.2020.72]

102 **Caliskan AM**, Karaaslan M, Inanli I, Caliskan S, Arslan M, Esra Cicek I, Eren I. The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study. *Int Clin Psychopharmacol* 2021; **36**: 30-33 [PMID: 33044315 DOI: 10.1097/YIC.0000000000000336]

103 **Correll CU**, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. *J Clin Psychiatry* 2016; **77**: 1-24 [PMID: 27732772 DOI: 10.4088/JCP.15032su1]

104 **Kishimoto T**, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, Correll CU. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. *Schizophr Bull* 2018; **44**: 603-619 [PMID: 29868849 DOI: 10.1093/schbul/sbx090]

105 **Tiihonen J**, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ* 2006; **333**: 224 [PMID: 16825203 DOI: 10.1136/bmj.38881.382755.2F]

106 **Tiihonen J**, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *Lancet* 2009; **374**: 620-627 [PMID: 19595447 DOI: 10.1016/S0140-6736(09)60742-X]

107 **Tiihonen J**, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. *Am J Psychiatry* 2011; **168**: 603-609 [PMID: 21362741 DOI: 10.1176/appi.ajp.2011.10081224]

108 **Tiihonen J**, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. *JAMA Psychiatry* 2017; **74**: 686-693 [PMID: 28593216 DOI: 10.1001/jamapsychiatry.2017.1322]

109 **Taipale H**, Mehtälä J, Tanskanen A, Tiihonen J. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up. *Schizophr Bull* 2018; **44**: 1381-1387 [PMID: 29272458 DOI: 10.1093/schbul/sbx176]

110 **Kerwin R**, Bolonna A. Management of clozapine-resistant schizophrenia. *Adv Psychiatr Treat* 2005; **11**: 101-106 [DOI: 10.1192/apt.11.2.101]

111 **Williams L**, Newton G, Roberts K, Finlayson S, Brabbins C. Clozapine-resistant schizophrenia: a positive approach. *Br J Psychiatry* 2002; **181**: 184-187 [PMID: 12204919 DOI: 10.1192/bjp.181.3.184]

112 **Jones C**, Hacker D, Meaden A, Cormac I, Irving CB, Xia J, Zhao S, Shi C, Chen J. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. *Cochrane Database Syst Rev* 2018; **11**: CD008712 [PMID: 30480760 DOI: 10.1002/14651858.CD008712.pub3]

113 **Kuipers E**. The management of difficult to treat patients with schizophrenia, using non-drug therapies. *Br J Psychiatry Suppl* 1996: 41-51 [PMID: 8968654]

114 **Hayward P**, David AS, Green N, Rabe-Hesketh S, Haworth E, Thompson N, Shaffer S, Hastilow S, Wykes T. Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial. *Clin SchizophrRelat Psychoses* 2009; **3**: 127-132 [DOI: 10.3371/CSRP.3.3.1]

115 **Suzuki T**, Uchida H, Watanabe K, Kashima H. Factors associated with response to clozapine in schizophrenia: a review. *Psychopharmacol Bull* 2011; **44**: 32-60 [PMID: 22506438]

116 **Kim D**. Indicators of response to clozapine treatment. *Ment Health Clin* 2015; **5**: 74-77 [DOI: 10.9740/mhc.2015.03.074]

117 **Chung C**, Remington G. Predictors and markers of clozapine response. *Psychopharmacology (Berl)* 2005; **179**: 317-335 [PMID: 15717209 DOI: 10.1007/s00213-005-2174-x]

118 **Okhuijsen-Pfeifer C**, Sterk AY, Horn IM, Terstappen J, Kahn RS, Luykx JJ. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis. *Neurosci Biobehav Rev* 2020; **111**: 246-252 [PMID: 31982601 DOI: 10.1016/j.neubiorev.2020.01.017]

119 **Samanaite R**, Gillespie A, Sendt KV, McQueen G, MacCabe JH, Egerton A. Biological Predictors of Clozapine Response: A Systematic Review. *Front Psychiatry* 2018; **9**: 327 [PMID: 30093869 DOI: 10.3389/fpsyt.2018.00327]

120 **Nielsen J**, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. *Acta Psychiatr Scand* 2011; **123**: 411-422 [PMID: 21534935 DOI: 10.1111/j.1600-0447.2011.01710.x]

121 **Subramanian S**, Völlm BA, Huband N. Clozapine dose for schizophrenia. *Cochrane Database Syst Rev* 2017; **6**: CD009555 [PMID: 28613395 DOI: 10.1002/14651858.CD009555.pub2]

122 **Alberich S**, Fernández-Sevillano J, González-Ortega I, Usall J, Sáenz M, González-Fraile E, González-Pinto A. A systematic review of sex-based differences in effectiveness and adverse effects of clozapine. *Psychiatry Res* 2019; **280**: 112506 [PMID: 31401291 DOI: 10.1016/j.psychres.2019.112506]

123 **Usall J**, Suarez D, Haro JM; SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. *Psychiatry Res* 2007; **153**: 225-231 [PMID: 17681611 DOI: 10.1016/j.psychres.2006.09.016]

124 **Albitar O**, Harun SN, Zainal H, Ibrahim B, Sheikh Ghadzi SM. Population Pharmacokinetics of Clozapine: A Systematic Review. *Biomed Res Int* 2020; **2020**: 9872936 [PMID: 31998804 DOI: 10.1155/2020/9872936]

125 **Aichhorn W**, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? *Drug Saf* 2006; **29**: 587-598 [PMID: 16808551 DOI: 10.2165/00002018-200629070-00004]

126 **Dragoi AM**, Radulescu I, Năsui BA, Pop AL, Varlas VN, Trifu S. Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19. *Brain Sci* 2020; **10** [PMID: 33187329 DOI: 10.3390/brainsci10110840]

127 **Pillinger T**, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020; **7**: 64-77 [PMID: 31860457 DOI: 10.1016/S2215-0366(19)30416-X]

128 **Martini F**, Spangaro M, Buonocore M, Bechi M, Cocchi F, Guglielmino C, Bianchi L, Sapienza J, Agostoni G, Mastromatteo A, Bosia M, Cavallaro R. Clozapine tolerability in Treatment Resistant Schizophrenia: exploring the role of sex. *Psychiatry Res* 2021; **297**: 113698 [PMID: 33440269 DOI: 10.1016/j.psychres.2020.113698]

129 **Iqbal E**, Govind R, Romero A, Dzahini O, Broadbent M, Stewart R, Smith T, Kim CH, Werbeloff N, MacCabe JH, Dobson RJB, Ibrahim ZM. The side effect profile of Clozapine in real world data of three large mental health hospitals. *PLoS One* 2020; **15**: e0243437 [PMID: 33290433 DOI: 10.1371/journal.pone.0243437]

130 **Oh S**, Lee TY, Kim M, Kim SH, Lee S, Cho S, Kim JH, Kwon JS. Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital. *NPJ Schizophr* 2020; **6**: 32 [PMID: 33214559 DOI: 10.1038/s41537-020-00122-3]

131 **Ruan CJ**, Zang YN, Wang CY, Cheng YH, Sun C, Spina E, de Leon J. Clozapine Metabolism in East Asians and Caucasians: A Pilot Exploration of the Prevalence of Poor Metabolizers and a Systematic Review. *J Clin Psychopharmacol* 2019; **39**: 135-144 [PMID: 30811372 DOI: 10.1097/JCP.0000000000001018]

132 **de Leon J**, Ruan CJ, Schoretsanitis G, De Las Cuevas C. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. *Psychother Psychosom* 2020; **89**: 200-214 [PMID: 32289791 DOI: 10.1159/000507638]

133 **de Leon J**, Rajkumar AP, Kaithi AR, Schoretsanitis G, Kane JM, Wang CY, Tang YL, Lin SK, Hong KS, Farooq S, Ng CH, Ruan CJ, Andrade C. Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview. *Indian J Psychol Med* 2020; **42**: 4-10 [PMID: 31997860 DOI: 10.4103/IJPSYM.IJPSYM\_379\_19]

134 **de Leon J**, Ruan CJ, Schoretsanitis G, Kane JM. Dose and safety concerns of clozapine: Worldwide package inserts need revisions. *Schizophr Res* 2020; **216**: 2-4 [PMID: 31926811 DOI: 10.1016/j.schres.2019.12.009]

135 **Suhas S**, Kumar V, Damodharan D, Sharma P, Rao NP, Varambally S, Venkatasubramanian G, Murthy P, Gangadhar BN. Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. *Schizophr Res* 2020; **222**: 195-201 [PMID: 32518001 DOI: 10.1016/j.schres.2020.05.057]

136 **Subramaniam M**, Ng C, Chong SA, Mahendran R, Lambert T, Pek E, Huak CY. Metabolic differences between Asian and Caucasian patients on clozapine treatment. *Hum Psychopharmacol* 2007; **22**: 217-222 [PMID: 17431927 DOI: 10.1002/hup.842]

137 **Munro J**, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. *Br J Psychiatry* 1999; **175**: 576-580 [PMID: 10789357 DOI: 10.1192/bjp.175.6.576]

138 **Citrome L**, McEvoy JP, Saklad SR. A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. *Clin Schizophr Relat Psychoses* 2016 [PMID: 27454214 DOI: 10.3371/CSRP.SACI.070816]

139 **Yuen JWY**, Kim DD, Procyshyn RM, Panenka WJ, Honer WG, Barr AM. A Focused Review of the Metabolic Side-Effects of Clozapine. *Front Endocrinol (Lausanne)* 2021; **12**: 609240 [PMID: 33716966 DOI: 10.3389/fendo.2021.609240]

140 **Simon V**, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. *J Clin Psychiatry* 2009; **70**: 1041-1050 [PMID: 19653979 DOI: 10.4088/jcp.08r04392]

141 **Tan MSA**, Honarparvar F, Falconer JR, Parekh HS, Pandey P, Siskind DJ. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. *Psychopharmacology (Berl)* 2021; **238**: 615-637 [PMID: 33410989 DOI: 10.1007/s00213-020-05746-y]

142 **Vasudev K**, Choi YH, Norman R, Kim RB, Schwarz UI. Genetic Determinants of Clozapine-Induced Metabolic Side Effects. *Can J Psychiatry* 2017; **62**: 138-149 [PMID: 27681143 DOI: 10.1177/0706743716670128]

143 **Taub S**, Hoshen M, Balicer R, Kamhi-Nesher S, Weizman A, Krivoy A. Metabolic predictors for mortality among patients treated with long-term clozapine - A longitudinal study. *Eur Neuropsychopharmacol* 2020; **41**: 63-69 [PMID: 32981820 DOI: 10.1016/j.euroneuro.2020.09.002]

144 **Zimbron J**, Khandaker GM, Toschi C, Jones PB, Fernandez-Egea E. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. *Eur Neuropsychopharmacol* 2016; **26**: 1353-1365 [PMID: 27496573 DOI: 10.1016/j.euroneuro.2016.07.010]

145 **Siskind DJ**, Leung J, Russell AW, Wysoczanski D, Kisely S. Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. *PLoS One* 2016; **11**: e0156208 [PMID: 27304831 DOI: 10.1371/journal.pone.0156208]

146 **Moeller FG**, Chen YW, Steinberg JL, Petty F, Ripper GW, Shah N, Garver DL. Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. *Ann Clin Psychiatry* 1995; **7**: 167-173 [PMID: 8721890 DOI: 10.3109/10401239509149622]

147 **Mustafa FA**, Burke JG, Abukmeil SS, Scanlon JJ, Cox M. "Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. *Pharmacopsychiatry* 2015; **48**: 11-14 [PMID: 25376977 DOI: 10.1055/s-0034-1394397]

148 **Bachmann CJ**, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, Coma Fusté A, Furu K, Garuoliené K, Hoffmann F, Hollingworth S, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Piovani D, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Siskind D, Skurtveit S, Verdoux H, Wang LJ, Zara Yahni C, Zoëga H, Taylor D. International trends in clozapine use: a study in 17 countries. *Acta Psychiatr Scand* 2017; **136**: 37-51 [PMID: 28502099 DOI: 10.1111/acps.12742]

149 **John AP**, Ko EKF, Dominic A. Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern. *Can J Psychiatry* 2018; **63**: 526-531 [PMID: 29682998 DOI: 10.1177/0706743718772522]

150 **Verdoux H**, Quiles C, Bachmann CJ, Siskind D. Prescriber and institutional barriers and facilitators of clozapine use: A systematic review. *Schizophr Res* 2018; **201**: 10-19 [PMID: 29880453 DOI: 10.1016/j.schres.2018.05.046]

151 **Farooq S**, Choudry A, Cohen D, Naeem F, Ayub M. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. *BJPsych Bull* 2019; **43**: 8-16 [PMID: 30261942 DOI: 10.1192/bjb.2018.67]

**Footnotes**

**Conflict-of-interest statement:** No potential conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** Fellow of the Royal College of Psychiatrists, United Kingdom, No. 11659; Fellow of the International Society for Affective Disorders, No. P0001064; Fellow of the National Academy of Medical Sciences, India, 2016, No. 129; and Life Fellow of the Indian Psychiatric Society, No. 03051.

**Peer-review started:** February 24, 2021

**First decision:** March 30, 2021

**Article in press:** July 13, 2021

**Specialty type:** Psychiatry

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cheng J **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:** Yuan YY

**Table 1 Key components of the current definitions of clozapine-resistant schizophrenia[12,14-16]**

|  |  |
| --- | --- |
| **Diagnosis** | **Diagnosis of schizophrenia using standardized criteria and after ruling out psychosis due to substance use or medical conditions** |
| Adequate clozapine treatment |  |
| Dose | 200-500 mg/d |
| Blood levels | ≥ 350 ng/mL |
| Treatment duration | 2-3 mo1 |
| Treatment adherence | ≥ 80% of prescribed doses for the duration of treatment |
| Response to clozapine |  |
| Baseline symptom severity and functional impairment | Moderately severe illness either globally or in positive and negative symptom domains assessed using standardized scales (CGI, BPRS, PANSS, SAPS, SANS). Moderate levels of functional impairment assessed using standardized scales (GAF, SOFAS) |
| Non-response | < 20% reduction in symptoms and minimal response in levels of functional impairment during an adequate trial of clozapine treatment |
| Persistence | Moderately severe illness and functional impairment should persist following an adequate trial of clozapine treatment |

1It has been proposed that duration of clozapine trials should be 2 mo for patients with aggression or self-harm, 3 mo for those with positive symptoms, and 4 mo for those with negative and cognitive symptoms[13].

BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression scale; GAF: Global Assessment of Functioning scale; PANSS: Positive and Negative Syndrome Scale; SANS: Scale for the Assessment of Negative Symptoms; SAPS: Scale for the Assessment of Positive Symptoms; SOFAS: Social and Occupational Functioning Scale.

**Table 2 Reviews of antipsychotic augmentation strategies in clozapine-resistant schizophrenia1**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Type of review** | **Details** | **Effect on positive or psychotic symptoms** | **Effect on negative or depressive symptoms** |
| Wagner *et al*[2], 2019 | Systematic review | 14 meta-analyses of FGA and SGA augmentation of clozapine. | Some evidence of benefits based on low-quality studies (SIGN grade B). |  |
| Roerig *et al*[8], 2019 | Systematic review | 4 meta-analyses and 1 naturalistic study of FGA and SGA augmentation of clozapine. | No benefits of antipsychotics when high-quality RCTs were considered. |  |
| Bartoli *et al*[22], 2019 | Meta-analysis | 12 RCTs of SGA augmentation of clozapine-risperidone (*n* = 5) and aripiprazole (*n* = 3). | No difference between SGA augmentation and placebo in improving positive symptoms. | A small benefit of SGA augmentation for negative and depressive symptoms. |
| Siskind *et al*[23], 2018 | Meta-analysis | 19 RCTs of FGA and SGA augmentation of clozapine-aripiprazole (*n* = 7), risperidone (*n* = 3), and amisulpiride (*n* = 2). | Evidence for benefit with aripiprazole, but effects were lost when low-quality studies were excluded. |  |
| Correll *et al*[24], 2017 | Meta-analysis | Meta-analysis of 29 previous meta-analyses of antipsychotic combinations-5 clozapine combinations examined. | Clozapine combinations no different from clozapine monotherapy for positive symptoms. | Clozapine combinations no different from clozapine monotherapy for negative symptoms. |
| Galling *et al*[25], 2017 | Meta-analysis | 20 RCTs of FGA and SGA augmentation of clozapine-risperidone (*n* = 6) and aripiprazole (*n* = 6). | No evidence for additional benefits of augmentation in double-blind, high-quality RCTs. | Improvement in negative symptoms with aripiprazole augmentation. No effect of augmentation on depressive symptoms. |
| Ortiz-Orendain *et al*[26], 2017 | Meta-analysis | 31 RCTs and quasi-RCTs of augmentation with SGAs (*n* = 26) and FGAs (*n* = 5) including clozapine augmentation. | Low-quality evidence that augmentation improves global clinical response. No specific effects on positive symptoms. | No effect of augmentation on negative symptoms. |
| Barber *et al*[27], 2017 | Meta-analysis | 5 RCTs of clozapine augmentation with SGAs or haloperidol. | Low-quality evidence that augmentation may improve global clinical response. Effects on positive symptoms not clear. | Effects on negative symptoms not clear. |
| Jiménez-Cornejo *et al*[28], 2016 | Meta-analysis | 17 prior meta-analyses and reviews of FGA and SGA augmentation (62 studies) of clozapine. | Little evidence that augmentation improves clinical response (> 20% reduction in PANSS/BPRS scores). |  |
| Taylor *et al*[29], 2012 | Meta-analysis | 14 RCTs of FGA and SGA augmentation of clozapine. | A small benefit in overall symptom reduction with augmentation. |  |
| Sommer *et al*[30], 2012 | Meta-analysis | 10 RCTs of FGA and SGA augmentation of clozapine. | One RCT showed that sulpiride augmentation led to overall symptom reduction. No specific effects on positive symptoms. | No specific effects on negative symptoms. |
| Porcelli *et al*[31], 2012 | Systematic review and meta-analysis | Systematic review of 25 studies of SGA augmentation of clozapine - risperidone (11 trials) and aripiprazole (6 trials). Meta-analysis of 5 RCTs of risperidone augmentation of clozapine. | Low quality evidence indicated benefits for aripiprazole and amisulpiride augmentation. No benefit of risperidone augmentation. | Some benefit of aripiprazole in reducing negative symptoms from 1 RCT. |

1Several other systematic reviews[9,12,14,32,33] and meta-analyses[17,34-37] have been unable to find significant benefits, while others have reported modest benefits for antipsychotic augmentation of clozapine[38-44].

BPRS: Brief Psychiatric Rating Scale; FGA: First-generation antipsychotic; RCT: Randomized controlled trial; PANSS: Positive and Negative Syndrome Scale; SGA: Second-generation antipsychotic; SIGN: Scottish Intercollegiate Guidelines Network.

**Table 3 Meta-analyses of antidepressant and mood stabilizer augmentation in clozapine-resistant schizophrenia**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ref.** | **Type of review** | **Details** | **Results** |
| Antidepressants |
| Siskind *et al*[23], 2018 | Meta-analysis | 10 RCTs of fluoxetine, paroxetine, duloxetine, and mirtazapine augmentation | Some evidence for fluoxetine augmentation in reducing in overall symptom severity based on 1 high-quality RCT. |
| Correll *et al*[24], 2017 | Meta-analysis | Analysis based on the earlier meta-analysis of Veerman *et al*[37] | No benefit of antidepressant augmentation on reduction in overall, positive, and negative symptom severity. |
| Veerman *et al*[37], 2014 | Meta-analysis | 4 RCTs of mirtazapine, duloxetine, and fluoxetine augmentation | No benefit of antidepressant augmentation on reduction in overall, positive, and negative symptom severity. |
| Sommer *et al*[30], 2012 | Meta-analysis | 4 RCTs of mirtazapine, citalopram, and fluoxetine augmentation | Some evidence for citalopram augmentation in reducing overall and negative symptom severity based on 1 RCT. |
| Mood stabilizers |
| Siskind *et al*[23], 2018 | Meta-analysis | 5 RCTs of valproate (*n* = 2), lamotrigine (*n* = 2), lithium (*n* = 1), and topiramate(*n* = 1) augmentation | Low-quality evidence for valproate and lithium augmentation in reducing total symptom severity. Reduction of positive and negative symptom severity by topiramate augmentation based on1 RCT. |
| Correll *et al*[24], 2017 | Meta-analysis | Analysis based on the earlier meta-analysis of Veerman *et al*[37] | No benefit of lamotrigine and topiramate augmentation on reduction in overall, positive, and negative symptom severity. |
| Zheng *et al*[50], 2017 | Meta-analysis | 22 RCTs of valproate (*n* = 9), lamotrigine (*n* = 8), and topiramate (*n* = 4) augmentation | Significant benefits for valproate and topiramate in reducing total and positive symptom severity but based on low-quality studies. No effects on clinical response. |
| Zheng *et al*[48], 2016 | Meta-analysis | 4 RCTs of topiramate augmentation | Significant benefits of topiramate augmentation in reducing overall, positive, and negative symptom severity. |
| Veerman *et al*[49], 2014 | Meta-analysis | 6 RCTs of lamotrigine and 4 RCTs of topiramate augmentation | No benefit of lamotrigine and topiramate augmentation on reduction in overall, positive, and negative symptom severity. |
| Sommer *et al*[30], 2012 | Meta-analysis | 7 RCTs of lamotrigine (*n* = 4) and topiramate (*n* = 3) augmentation | Benefits of lamotrigine and topiramate augmentation for total and positive symptoms based on single RCTs that did not persist on further analysis. |
| Tiihonen *et al*[47], 2009 | Meta-analysis | 5 RCTs of lamotrigine augmentation | Evidence for benefit of lamotrigine augmentation in reducing overall, positive, and negative symptom severity. |

RCT: Randomized controlled trial.

**Table 4 Electroconvulsive therapy and recurrent transcranial magnetic stimulation augmentation in clozapine-resistant schizophrenia**

|  |
| --- |
| **ECT** |
| **Ref.** | **Study/review** | **Details** | **Results** |
| Masoudzadeh *et al*[56], 2007 | Controlled trial, (non-randomized, non-blinded) | 18 patients with TRS; 3 groups of clozapine-ECT treatment, only clozapine and only ECT treatment (*n* = 6 each) | Significant differences between the clozapine- ECT combination and monotherapy groups in reduction of PANSS scores. |
| Petrides *et al*[54], 2015 | Single-blind cross-over RCT | 39 patients with TRS randomized to clozapine-ECT (*n* = 20) and clozapine only treatment (*n* = 19) | Significantly greater response on BPRS psychosis & CGI scores in the clozapine-ECT combination group. |
| Melzer-Ribeiro *et al*[55], 2017 | Single-blind sham-controlled RCT | 23 patients with CRS randomized to treatment with clozapine-ECT (*n* = 13) and clozapine-sham ECT (*n* = 10) | No significant differences between the groups on PANSS total and positive symptom scores and CGI scores. |
| Kupchik *et al*[57], 2000 | Systematic review | Case reports of 36 patients with TRS and clozapine non-responders | 67% of the patients on the clozapine-ECT combination showed good response. |
| Braga *et al*[58], 2005 | Systematic review | 12 case reports or chart reviews of patients with TRS and clozapine non-responders | The clozapine-ECT combination was efficacious. |
| Havaki-Kontaxaki *et al*[59], 2006 | Systematic review | One open trial and 6 case studies of patients with CRS | 73% patients on the clozapine-ECT combination showed marked improvement. |
| Pompili *et al*[60], 2013 | Systematic review | 31 studies examining indications for ECT in schizophrenia | The clozapine-ECT combination was efficacious in patients resistant to medications. |
| Grover *et al*[61], 2015 | Systematic review | 40 studies, mainly case reports of patients with CRS | Short-term response rates of the clozapine-ECT combination varied from 37%-100%. |
| Lally *et al*[62], 2016 | Systematic review and meta-analysis | Pooled analysis of patients with TRS treated with clozapine and ECT based on 4 open trials, 2 controlled trials (1 RCT)1, 2 chart reviews, 6 case series, and 15 case reports | Pooled response rate with the clozapine-ECT combination was 54% on meta-analysis. Systematic review showed 76% overall response rate with clozapine-ECT treatment and a relapse rate of 32%. |
| Manubens *et al*[63], 2016 | Systematic review and meta-analysis | 6 systematic reviews of ECT in TRS including 6 controlled trials of the clozapine-ECT combination in clozapine non-responders (1 RCT)1 | Modest effect of ECT in augmenting clozapine response with low certainty of evidence. |
| Ahmed *et al*[64], 2017 | Systematic review and meta-analysis | 9 studies of the clozapine-ECT combination in TRS including 2 controlled trials (1 RCT)1, 3 open trials, and 4 case series/chart-reviews *vs* 9 studies of ECT-non-clozapine antipsychotic combination | The ECT-clozapine combination was significantly better than the ECT-non-clozapine antipsychotic combinations in reducing positive symptoms on the PANSS and the BPRS. |
| Wang *et al*[52], 2018 | Meta-analysis | 18 RCTs of clozapine augmentation in CRS (17 from China and 1 from the United States1) | Adjunctive ECT was superior to clozapine monotherapy in reducing positive symptoms after 1–2 wk but with moderate effect size. |
| rTMS |
| Wagner *et al*[66], 2020 | Meta-analysis | Pooled data from 10 RCTs for 131 patients with persistent positive and negative symptoms being treated with clozapine | No differences between active and sham rTMS in improving clinical response and reducing PANSS scores. No benefit of rTMS augmentation for patients with persistent symptoms on clozapine. |

1The RCT from United States is by Petrides *et al*[54].

BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression scale; CRS: Clozapine-resistant schizophrenia; ECT: Electroconvulsive therapy; PANSS: Positive and Negative Syndrome Scale; RCT: Randomized controlled trial; rTMS: Recurrent transcranial magnetic stimulation; TRS: Treatment resistant schizophrenia.

**Table 5 Psychosocial augmentation strategies in clozapine-resistant schizophrenia**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ref.** | **Study/participants** | **Interventions** | **Results** |
| Studies |
| Pinto *et al*[69], 1999 | Single-blind RCT of 41 patients with TRS started on clozapine | CBT and social skills training *vs* supportive therapy for 6 mo. | Significant reductions in positive and negative symptom severity in the CBT group. |
| Buchain *et al*[70], 2003 | Single-blind RCT of 41 patients with TRS started on clozapine | Occupational therapy and clozapine *vs* clozapine alone for 6 mo. | Significant improvements in the occupational performance and interpersonal relationships with OT. |
| Barretto *et al*[71], 2009 | Single-blind RCT of 21 patients with CRS | CBT *vs* supportive treatment (“befriending”) for 21 wk. | Significant reductions in overall symptom severity and improvement in quality of life with CBT. |
| Morrison *et al*[75], 2018 | Double-blind RCT of 425 patients with CRS | CBT *vs* usual treatment for 9 mo. Follow-up for 21 mo. | Significant reductions in PANSS scores with CBT at 9 mo but no differences at 21 mo. |
| Sensky *et al*[72], 2000; Valmaggia *et al*[73], 2005; Edwards *et al*[74], 2011 | RCTs of patients with TRS (*n* = 48-90) including patients on clozapine or clozapine non-responders | CBT *vs* supportive treatment or clozapine alone or comparisons with combinations of CBT with other antipsychotics. | Significant reductions in positive, negative, and depressive symptom severity, improvement in clinical response and functioning with CBT; benefits at end of treatment usually maintained during follow-up. |
| Reviews |
| Ranasinghe *et al*[33], 2014 | Systematic review | Review of the 2 CBT and 1 OT trial mentioned above. | Benefits of psychosocial interventions noted for overall symptom severity, quality of life, and social functioning. |
| Polese *et al*[68], 2019 | Systematic review & meta-analysis | Review of all the above trials and meta-analysis of 4 RCTs including Morrison *et al*[75]. | Benefits of psychosocial interventions noted for overall and positive symptom severity. |

CBT: Cognitive-behavioural therapy; CRS: Clozapine resistant schizophrenia; PANSS: Positive and Negative Syndrome Scale; OT: Occupational therapy; TRS: Treatment resistant schizophrenia; RCT: Randomized controlled trial.

**Table 6 Augmentation of clozapine with long-acting antipsychotic injections in clozapine-resistant schizophrenia**

|  |  |  |
| --- | --- | --- |
| **Ref.** | **Study details** | **Results** |
| Kim *et al*[92], 2010 | 4 patients treated with clozapine and risperidone LAI for 1 yr | Reduction in number and length of hospitalizations and improvement in social skills after LAI addition. Fewer side effects with the combination. |
| Malla *et al*[93], 2013 | One patient with poor response to clozapine treated with clozapine and an LAI | Improvement in symptoms and social functioning without any increase in side effects with combination treatment. |
| Baruch *et al*[94], 2014 | 8 patients, 6 with TRS. Treated with olanzapine LAI and clozapine or other antipsychotics up to 2 yr | Reduction in aggression in all 8 patients and in symptom severity in 6 patients. |
| Maia-de-Oliveira *et al*[95], 2015 | 2 patients with CRS treated with clozapine and paliperidone LAI for 9-10 mo | Remission of positive symptoms after LAI augmentation. |
| [Kasinathan](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kasinathan%20J%5BAuthor%5D&cauthor=true&cauthor_uid=27721969) *et al*[96], 2016 | 9 patients with TRS and comorbid personality disorders/substance use and violence; 1 on clozapine but non-adherent treated with olanzapine LAI combination | 1 yr of retrospective pre- and post-LAI comparisons showed significant improvements in psychotic symptoms, violence, and reduction in number and length of hospitalizations and emergency visits. |
| Sepede *et al*[97], 2016 | One patient with poor response to clozapine treated with clozapine and aripiprazole LAI for 1 yr | Symptoms reduced by 50% with the combination without any increase in side effects. |
| Oriolo *et al*[98], 2016 | Retrospective observational of 23 patients with TRS in whom paliperidone LAI was added toclozapine | Significant reductions in severity of global, positive, negative, depressive, and cognitive symptoms with the combination. Significantly lower doses of clozapine and paliperidone LAI required with combination treatment *vs* monotherapy. |
| Souaiby *et al*[99], 2017 | Retrospective observational study with a mirror-image design of 20 patients with TRS treated with clozapine and LAIs for 32 mo | Significant reductions in number and length of hospitalizations during 32 mo of combination treatment *vs* 1 yr of monotherapy. No increase in side effects with the combination. |
| Grimminck *et al*[100], 2020 | Retrospective observational study with a mirror- image design of 20 patients with poor response to clozapine or LAIs treated with clozapine and LAI combinations for 2 yr | Significant reductions in hospital admissions and emergency visits during 2 yr of combination treatment *vs* 2 yr of monotherapy. Overall improvement in behaviour and social functioning but no change in symptoms. |
| Bioque *et al*[101], 2020 | Retrospective observational study with a mirror- image design of 50 patients with TRS treated with clozapine and paliperidone LAI for 6 mo | Significant reductions in BPRS scores, emergency visits, number and length of hospitalizations, and number and severity of adverse effects as well as significant improvements in social functioning during 6 mo of combination treatment *vs* 6 mo of monotherapy. |
| Caliskan *et al*[102], 2021 | Retrospective observational study with a mirror- image design in 29 patients with TRS treated with clozapine and LAI combinations for 1 yr | Significant reductions in number of relapses and number and length of hospitalizations during 1 yr of combination treatment *vs* 1 yr of monotherapy. No differences in side effects with the combinations. |

BPRS: Brief Psychiatric Rating Scale; CRS: Clozapine resistant schizophrenia; LAI: Long-acting antipsychotic injection; TRS: Treatment resistant schizophrenia.

**Table 7 Scandinavian nationwide cohort studies of antipsychotic treatment**

|  |  |  |
| --- | --- | --- |
| **Ref.** | **Study details** | **Results** |
| Tiihonen *et al*[105], 2006, Finland | 2230 inpatients followed up for 3.6 yr | Significantly lower risks of rehospitalization or treatment discontinuation in patients on perphenazine LAI, clozapine, or olanzapine *vs* those on oral haloperidol. |
| Tiihonen *et al*[106], 2009, Finland | 66881 outpatients followed up for 11 yr | Clozapine was associated with a substantially lower mortality than any other antipsychotics singly or in combination, with perphenazine as a comparator. |
| Tiihonen *et al*[107], 2011, Finland | 2588 inpatients followed up for 2 mo after discharge | Significantly lower risks of rehospitalization with LAIs than oral medications. Clozapine and olanzapine were associated with significantly lower risk of rehospitalization than risperidone. |
| Tiihonen *et al*[108], 2017, Sweden | 29823 patients followed up for 5.7 yr | Significantly lower risks of rehospitalization and of treatment failure1 with LAIs and clozapine *vs* no antipsychotic treatment. |
| Taipale *et al*[109], 2018, Finland | 62250 inpatients followed up for 20 yr | Significantly lower risks of rehospitalization with LAIs and clozapine *vs* no antipsychotic treatment in first episode and chronic schizophrenia. |
| Tiihonen *et al*[77], 2019, Finland | 62250 inpatients on antipsychotic monotherapy or antipsychotic combinations followed up for 14 yr | Combination of clozapine and aripiprazole was associated with significantly lower risk of rehospitalization and mortality than clozapine alone in first episode and chronic schizophrenia. Clozapine monotherapy was associated with the most favourable outcomes compared to other antipsychotics. |
| Luykx *et al*[82], 2020, Finland | 2250 patients on clozapine treatment followed up for more than 1 yr before discontinuation | Compared to no antipsychotic treatment, significantly lower risks of rehospitalization with re-institution of clozapine alone, oral olanzapine, and antipsychotic combinations. Significantly lower risks of treatment failure**1**with aripiprazole LAI, re-institution of clozapine alone, and oral olanzapine. |

1Treatment failure included re-hospitalization, suicide attempt, treatment discontinuation, medication switch, or death.

LAI: Long-acting antipsychotic injection.

**Table 8 Steps for ensuring optimal clozapine treatment[65,81,110,111,120,123,132]**

|  |
| --- |
| **Steps for ensuring optimal clozapine treatment** |
| Adequate assessment | Diagnosis should be established properly. Comorbid conditions should be looked for. Adherence should be determined. Symptoms and other outcome domains should be preferably rated using validated instruments. Caregiver burden and coping should be assessed. Stressors and adverse circumstances should be evaluated. |
| Proper dosing | Inter-individual and ethnic variability in optimal doses should be considered. If facilities for serum levels are available, doses should be titrated to ensure plasma levels > 350 ng/mL. Doses should be increased slowly with careful monitoring of side effects to reduce the burden of dose-dependent side effects. |
| Adequate duration | A minimum of 2-3 mo is considered necessary. Durations could be shorter in those with high risk of aggression or self-harm. Durations could be longer in those with negative or cognitive symptoms and in partial responders. |
| Managing side effects | Many of the common side effects of clozapine can be managed by slow titration, using the least effective dose, reducing doses when side effects develop, adding medications, or adopting lifestyle changes to counter side effects. Additionally, careful monitoring should be carried out for the more serious and idiosyncratic adverse reactions such as agranulocytosis and cardiopulmonary complications. |
| Managing non-adherence | Careful monitoring of adherence based on multiple sources is necessary. Managing side effects, educating patients to deal with negative attitudes to clozapine, developing a trusting alliance to improve motivation, caregiver education and support to increase their involvement in the patient’s care may help. These measures should ideally be initiated right at the beginning of treatment. Use of long-acting antipsychotic injections may be considered. |
| Collaboration with patients and caregivers | Both patients and caregivers should be the focus of treatment. Measures should be tailored according to their needs. Goals of treatment should be reduction of symptoms and distress, improving support, forging effective alliances, and promoting patient and caregiver engagement. Simple psychosocial measures including cognitive or behavioural strategies, psychoeducation, and emotional and practical support should be implemented at the start of treatment or as early as possible. More structured interventions can be tried depending on availability of resources and expertise. |
| Addressing clinician related barriers | Clinicians’ lack of awareness and experience of clozapine treatment and negative attitudes towards clozapine use should be addressed by proper education, dissemination of information, and dedicated facilities. |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**